Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
J&J shares fall after court refuses to block Zytiga genericsJohnson & Johnson’s share price took a beating this week after the US appeals court declined its bid Share XJ&J shares fall after court refuses to block Zytiga genericshttps://pharmaphorum.com/news/jj-shares-fall-after-court-refuses-to-block-zytiga-generics/
Bayer plans filings for prostate cancer drug darolutamideBayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped Share XBayer plans filings for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-plans-filings-for-prostate-cancer-drug-darolutamide/
Clovis hopes to get ahead of rivals in prostate cancer with RubracaClovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year’s Share XClovis hopes to get ahead of rivals in prostate cancer with Rubracahttps://pharmaphorum.com/news/clovis-hopes-to-get-ahead-of-rivals-in-prostate-cancer-with-rubraca/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
UK biotech Azeria pioneers research into cancer target FOXA1A new UK biotech, Azeria Therapeutics has started on a mission to develop breakthrough treatments for drug-resistant breast Share XUK biotech Azeria pioneers research into cancer target FOXA1https://pharmaphorum.com/news/uk-biotech-azeria-pioneers-research-into-cancer-target-foxa1/
Prostate drug approved for use in non-metastatic casesThe US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic Share XProstate drug approved for use in non-metastatic caseshttps://pharmaphorum.com/news/prostate-drug-approved-for-use-in-non-metastatic-cases/
J&J gets quick approval for new next-gen prostate cancer drugThe FDA has approved Johnson & Johnson’s next generation prostate cancer drug, apalutamide in an early but tough Share XJ&J gets quick approval for new next-gen prostate cancer drughttps://pharmaphorum.com/news/jj-gets-quick-approval-new-next-gen-prostate-cancer-drug/
J&J files next generation prostate cancer drug in EuropeAfter having filed its new prostate cancer drug apalutamide with the FDA in October, Johnson & Johnson have Share XJ&J files next generation prostate cancer drug in Europehttps://pharmaphorum.com/news/jj-files-next-generation-prostate-cancer-drug-europe/
